The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis

OBJECTIVE: Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). The pathways affected by tofacitinib and the effects on gene expression in situ are unknown. Therefore, tofacitinib effects on synovial pathobiology were investigated. METHODS: A randomised...

Descripción completa

Detalles Bibliográficos
Autores principales: Boyle, D L, Soma, K, Hodge, J, Kavanaugh, A, Mandel, D, Mease, P, Shurmur, R, Singhal, A K, Wei, N, Rosengren, S, Kaplan, I, Krishnaswami, S, Luo, Z, Bradley, J, Firestein, G S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Basic and Translational Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4431345/
https://www.ncbi.nlm.nih.gov/pubmed/25398374
http://dx.doi.org/10.1136/annrheumdis-2014-206028

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4431345/
https://www.ncbi.nlm.nih.gov/pubmed/25398374
http://dx.doi.org/10.1136/annrheumdis-2014-206028

Ejemplares similares